- Home
- PTLE vs VYNE Comparison
PTLE vs VYNE Comparison
Compare PTLE & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLE
- VYNE
- Stock Information
- Founded
- PTLE 2013
- VYNE 2003
- Country
- PTLE Singapore
- VYNE United States
- Employees
- PTLE N/A
- VYNE N/A
- Industry
- PTLE Oil Refining/Marketing
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- PTLE Energy
- VYNE Health Care
- Exchange
- PTLE Nasdaq
- VYNE Nasdaq
- Market Cap
- PTLE 16.4M
- VYNE 16.0M
- IPO Year
- PTLE 2024
- VYNE 2018
- Fundamental
- Price
- PTLE $0.28
- VYNE $0.89
- Analyst Decision
- PTLE
- VYNE Strong Buy
- Analyst Count
- PTLE 0
- VYNE 2
- Target Price
- PTLE N/A
- VYNE $6.25
- AVG Volume (30 Days)
- PTLE 28.5M
- VYNE 332.1K
- Earning Date
- PTLE 02-21-2025
- VYNE 08-13-2025
- Dividend Yield
- PTLE N/A
- VYNE N/A
- EPS Growth
- PTLE N/A
- VYNE N/A
- EPS
- PTLE N/A
- VYNE N/A
- Revenue
- PTLE $98,133,646.00
- VYNE $605,000.00
- Revenue This Year
- PTLE N/A
- VYNE $42.51
- Revenue Next Year
- PTLE N/A
- VYNE N/A
- P/E Ratio
- PTLE N/A
- VYNE N/A
- Revenue Growth
- PTLE N/A
- VYNE 43.03
- 52 Week Low
- PTLE $0.17
- VYNE $0.85
- 52 Week High
- PTLE $15.78
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- PTLE N/A
- VYNE 30.97
- Support Level
- PTLE N/A
- VYNE $0.95
- Resistance Level
- PTLE N/A
- VYNE $0.96
- Average True Range (ATR)
- PTLE 0.00
- VYNE 0.07
- MACD
- PTLE 0.00
- VYNE 0.02
- Stochastic Oscillator
- PTLE 0.00
- VYNE 18.35
About PTLE PTL LTD Ordinary Shares
PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, primarily serving the Asia Pacific market. As a bunker facilitator, the Group's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers in a timely manner; and handling disputes, mainly in relation to quality and quantity issues on marine fuel, if any.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.